The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Unidentified Participant - Oppenheimer & Co. Inc - Analyst
: This is Chung on the line for Jay and just want to congratulations again on the very impressive results we shared recently.
Just wondering first, have you maybe started to engage with regulators, with the 16 week data and since you started some activity to prepare for
the phase 3 initiation, any color you can share how are you thinking about the trial design and also maybe the number of trials you are planning
for the phase 3 program. And maybe separately just like wondering you saw some partnership opportunity for RPA and AT and specifically when
would be the optimal time to bring a partner on board and any kind of a characteristic would you define the partner.
Thank you so much.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 07, 2025 / 9:00PM, NKTR.OQ - Q2 2025 Nektar Therapeutics Earnings Call
Question: Unidentified Participant - Oppenheimer & Co. Inc - Analyst
: Got it.
Thank you so much and congrats again on the progress.
Question: Yasmeen Rahimi - Piper Jaffray Inc - Analyst
: Good afternoon team. Congrats on all the updates and all the great commentary. I guess my question is, as the next near term data catalyst is the
upcoming AA readout, if JZ, you could walk us through how your thought process around what is a competitive product profile to advance to a
later stage development and whether also we will see at the time of the top line data some of the patients who continued into the longer extension,
or should we not expect that, and I'll jump back into the queue.
Question: Yasmeen Rahimi - Piper Jaffray Inc - Analyst
: Thank you so much, Daisy.
Question: Julian Harrison - BTIG LLC - Analyst
: Hi, thank you for taking the question, and congrats on all the recent progress. It's great to hear that you plan to include biologic experience, atopic
term in your first registrational program for ResPEG. Can you remind us of what underpins your confidence that respe will be active in the segment?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 07, 2025 / 9:00PM, NKTR.OQ - Q2 2025 Nektar Therapeutics Earnings Call
Question: Julian Harrison - BTIG LLC - Analyst
: Very helpful.
Thank you.
Question: Arthur He, Ph.D. - H C Wainwright & Co LLC (Pre-Merger) - Analyst
: Are team. Congrats on the progress report.
Question: Arthur He, Ph.D. - H C Wainwright & Co LLC (Pre-Merger) - Analyst
: The potential of the pivotal study for the respect for the.
AD, regarding the biological experimentation for.
What's.
Your thoughts around the.
The biological.
Prior.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 07, 2025 / 9:00PM, NKTR.OQ - Q2 2025 Nektar Therapeutics Earnings Call
Biological therapy? Would that be heavily focused on the.
New texting.
Exam patient or you going to do kind of the basket patient cohort?
Question: Mayank Mamtani - B. Riley Securities Holdings Inc - Analyst
: Hi Dean, thanks for taking our questions and congrats on a very productive 2nd quarter. As part of the phase 3, I was wondering what your
expectations for the induction efficacy primary endpoint, duration of therapy would be knowing that you. Not getting to the peak and its efficacy
at 16 weeks and also the thought you might be putting in to get the remit of efficacy signal and obviously, is there anything to learn from the Ox
trials that are sort of trying to get to a comparable goal and then I have a couple of follow up.
Question: Mayank Mamtani - B. Riley Securities Holdings Inc - Analyst
: Very helpful, JZ and maybe just staying in the same topic of learning from A40, the alopecia data we've seen so far maybe doesn't get up to the
benchmarks you shared for jack inhibitors, but was just curious given that you know you're somewhere in the middle in AD does that read through
to the alopecia trial and maybe just lastly for Harvard, any updates on the lili litigation. And if your belief, with the results now with you, any changes
to your belief in the outcome and the related liabilities that you might be claiming, thanks for taking your questions.
Question: Arthur He, Ph.D. - H C Wainwright & Co LLC (Pre-Merger) - Analyst
: Appreciate the credit.
Question: Cha Cha Yang, MS, MBA - Jefferies LLC - Analyst
: Yes.
Okay, wonderful. Hi, this is Chacha on for Roger Song. I was hoping that you could give us any updates on your studies being done to better
understand the ISRs, whether that's from a mechanistic perspective, or if you could give us any updates in regards to developing strategies for
mitigating them upon commercialization.
Question: Jessica Fye - JPMorgan Chase & Co - Analyst
: Hey guys, good evening. Thanks for taking my questions. For Respe for AD, can you just speak to your comfort level with the powering of the
maintenance phase of that trial after the dropouts and the induction portion? I think you had sort of planned for some attrition here. Just want to
make sure that you still feel good about the powering for the the maintenance phase, and I think when you kind of presented the top line induction
data in AD, we're sort of benchmarking off of aux 40. You spend a minute talking about why you think that's the right comp for this product.
Thank you.
| 
